NICE draft guidance recommends pertuzumab for early treatment of breast cancer
NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes. (Source: NHS Networks)
Source: NHS Networks - February 19, 2019 Category: UK Health Source Type: news

' Remarkable' New Benefit in HER2+ Breast Cancer'Remarkable' New Benefit in HER2+ Breast Cancer
Roughly half of patients with HER2-positive, early stage breast cancer have residual disease after initial drug therapy and then surgery; T-DM1 may improve their outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of
Source: CancerNetwork - February 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Breast cancer cells shifted into HER2 positive status with bold new strategy
(Scripps Research Institute) One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2019 Category: Cancer & Oncology Source Type: news

Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?
The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - February 5, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 5, 2019 Category: Pharmaceuticals Source Type: news

Identification of HER2 IHC-Negative, FISH+ Breast Cancers Identification of HER2 IHC-Negative, FISH+ Breast Cancers
Both immunohistochemistry for protein expression or fluorescent in situ hybridization for gene amplification can be used to determine HER2 status in breast cancer--but what if they don't agree?American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 4, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Use of Image Analysis to ID HER2 Status in Breast Cancer Outlined
FRIDAY, Feb. 1, 2019 -- Recommendations have been developed to improve accuracy, precision, and reproducibility in the interpretation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) results for breast cancer with use of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2019 Category: Pharmaceuticals Source Type: news

NICE recommends pertuzumab for early HER2-positive breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Guide for HER2 Testing That's Not'by Eye'Guide for HER2 Testing That's Not'by Eye '
Quantitative image analysis is an alternative to breast cancer diagnostic tests that require a visual review by a pathologist.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

High Response Rate in HER2+ Esophagogastric Cancer
(MedPage Today) -- Summary findings from the Gastrointestinal Cancers Symposium (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 23, 2019 Category: Primary Care Source Type: news

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
Drug-induced compensatory signaling and subsequent rewiring of the signaling pathways that support cell proliferation and survival promote the development of acquired drug resistance in tumors. Here, we sought to analyze the adaptive kinase response in cancer cells after distinct treatment with agents targeting human epidermal growth factor receptor 2 (HER2), specifically those that induce either only temporary cell cycle arrest or, alternatively, apoptosis in HER2-overexpressing cancers. We compared trastuzumab, ARRY380, the combination thereof, and a biparatopic, HER2-targeted designed ankyrin repeat protein (DARPin; spe...
Source: Signal Transduction Knowledge Environment - January 22, 2019 Category: Science Authors: Schwill, M., Tamaskovic, R., Gajadhar, A. S., Kast, F., White, F. M., Plückthun, A. Tags: STKE Research Resources Source Type: news

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy No anti-HER2 therapies are currently approved for H... Biopharmaceuticals, Oncology Daiichi Sankyo, trastuzumab, breast cancer, HER2 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 14, 2019 Category: Pharmaceuticals Source Type: news

Can Dasatinib Improve Trastuzumab Efficacy in HER2+ Breast Cancer?
Researchers tested whether combining trastuzumab/paclitaxel with dasatinib would have a high response rate in patients with metastatic HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Alternative Chemo Formulations May Help Reduce Cardiac Toxicity In HER2+ Breast Cancer
The Opti-HER HEART trial examined whether liposomal formulations of chemotherapy agents may reduce cardiac toxicity in HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - January 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

18-Gene Signature for Predicting Relapse in Breast Cancer 18-Gene Signature for Predicting Relapse in Breast Cancer
Prediction of metastasis risk for ER+/HER2- breast cancer is similar between a 10-year gene signature and commercial signatures.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer
Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 27, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

Delayed-Phase MRI Accurate in Evaluating Residual Breast Tumor Size
Lobular or HER2 –negative cancers are underestimated in size at MRI compared with ductal or other subtypes. (Source: Diagnostic Imaging)
Source: Diagnostic Imaging - December 14, 2018 Category: Radiology Authors: Diagnostic Imaging Staff Tags: Breast Imaging MRI Source Type: news

FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
INCHEON, South Korea& JERUSALEM--(BUSINESS WIRE) December 14, 2018 --Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb), a HER2/neu... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Charles E. Geyer Jr, MD Source Type: news

Hormonal therapies may cause treatment resistance in breast cancer
Metastatic breast cancer treated with hormonal therapies can acquire mutations in HER2 and become treatment resistant, according to data published inNature Genetics.   MedicalXpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 12, 2018 Category: Endocrinology Source Type: news

Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity? (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity? (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Closer look at TAILORx confirms lack of chemo benefit regardless of race or ethnicity
(ECOG-ACRIN Cancer Research Group) Before TAILORx, there was uncertainty about treatment for women with hormone receptor-positive, HER2-negative, node-negative breast cancer and a score of 11-25 on a tumor gene test. The trial was designed to address this question and provides a definitive answer: no benefit from chemotherapy for women over 50 with a score of 11-25; 50 years old or younger with a score of 11-15; and any age with a score of 0-10. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2018 Category: International Medicine & Public Health Source Type: news

Circulating tumor cell count could help choose treatment for metastatic breast cancer patients
(American Association for Cancer Research) Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according to data from the phase III STIC CTC clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. In the case of discrepancy between CTC count-based treatment choice and physician's choice of treatment, frontline chemotherapy was associated with a significant gain in overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Black women have worse breast cancer outcomes despite receiving similar treatment as white women
(American Association for Cancer Research) Even with equivalent treatments in women with hormone receptor-positive, HER2-negative breast cancer, black women had significantly higher breast cancer recurrence and increased overall mortality compared to white women in a large phase III clinical trial, TAILORx, according to data presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 6, 2018 Category: International Medicine & Public Health Source Type: news

T-DM1: A New Adjuvant Standard in High-Risk HER2+ Breast Ca?
(MedPage Today) -- Substantial improvements in survival outcomes in KATHERINE trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 5, 2018 Category: Hematology Source Type: news

New Standard When HER2+ Breast Cancer Isn't Cleared New Standard When HER2+ Breast Cancer Isn't Cleared
' Practice-changing'results support adjuvant trastuzumab emtansine in patients with HER2+ early stage breast cancer who have residual disease following surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

SABCS: T - DM1 Cuts Recurrent Invasive HER2 + Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Drug Halves Recurrence for Common Breast Cancer
All of the women in the new trial had undergone a standard treatment scenario. First, they received traditional chemotherapy and the drug Herceptin (trastuzumab) -- an antibody that targets HER2-positive cancer cells. Then they had surgery to remove any remaining cancer. (Source: WebMD Health)
Source: WebMD Health - December 5, 2018 Category: Consumer Health News Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk
WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Ribociclib cost effective for HR+/HER2 − advanced breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
(ECCO-the European CanCer Organisation) An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

Will tarloxotinib finally break the HER2 barrier in lung cancer?
(University of Colorado Anschutz Medical Campus) By pairing a potent HER2/EGFR inhibitor with a targeting mechanism specific to tumors, researchers show that tarloxotinib is far more active against HER2 lung cancer cell lines than even the most successful existing HER2/EGFR inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 7, 2018 Category: Cancer & Oncology Source Type: news

Is a Shorter Trastuzumab Duration a Cost-Effective Option in HER2+ Breast Cancer?
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

A Closer Look at HER2-Targeted Therapies
Dr. Adam Brufsky speaks withCancer Network about the evolution and future of HER2-targeted therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: Adam Brufsky, MD, PhD Source Type: news

First PI3K Inhibitor to Improve Outcomes in HR+/HER2 − Breast Cancer
The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2 − breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

City of Hope opens CAR T trial for HER2 breast cancer patients with brain metastases
(City of Hope) Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial -- the first to focus on HER2-postive breast cancer patients with brain metastases -- is now enrolling potential participants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2018 Category: International Medicine & Public Health Source Type: news

Could Low-Risk Breast Cancer Patients Benefit From Shorter Trastuzumab Treatment?
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - October 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

PI3K Inhibitor Doubles PFS in HR+/HER2- Breast Cancer
(MedPage Today) -- Benefit limited to patients with PIK3CA mutations (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 22, 2018 Category: Primary Care Source Type: news

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
(European Society for Medical Oncology) Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

A New Type of Treatment Shows Promise Against Aggressive Breast Cancer
This study is proof of principle that we should keep going,” Litton says. She is investigating whether there is a way for people who have already started chemotherapy to learn whether they will respond to the standard cycle of chemotherapy drugs, or should be switched to immunotherapy combinations for better results. Adams is also hopeful that other immunotherapy drugs may be developed that are more effective in activating the immune system against breast cancer cells specifically. “I expect these results will really invigorate the field and bring new research to help patients,” she says. (Source: TIME: Health)
Source: TIME: Health - October 20, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized breast cancer news healthytime Source Type: news

HER2+ early breast cancers where shorter-course trastuzumab could be an option
(European Society for Medical Oncology) Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news